Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

18.72 USD +0.11 (+0.59%)
Streaming Delayed Price Updated: 7:00 AM EST, Jan 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Atara Biotherap

< Previous 1 2 3 4 5 6 7 Next >
Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research (AACR) Annual Meeting
Presentation to Report Clinical Trial Results in Nasopharyngeal Cancer 
From GlobeNewswire News Releases
Atara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by... 
From GlobeNewswire News Releases
Atara Bio to Present at the Cowen and Company 36th Annual Health Care Conference
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by... 
From GlobeNewswire News Releases
Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD)
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by... 
From GlobeNewswire News Releases
Atara Bio Announces Participation in Two Upcoming Investor Conferences
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic... 
From GlobeNewswire News Releases
Atara Biotherapeutics Inc (NASDAQ:ATRA) Shareholder Alert: Investigation Announced
San Diego, CA -- (SBWIRE) -- 01/26/2016 -- An investigation for shareholders in Atara Biotherapeutics Inc (NASDAQ:ATRA) shares over potential securities laws violations was announced. 
From SBWire - Latest Press Releases
Atara Bio to Present at the 34th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic... 
From GlobeNewswire News Releases
Atara Bio Added to the NASDAQ Biotechnology Index
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic... 
From GlobeNewswire News Releases
Atara Bio Announces Results From the Phase 2 Proof-of-Concept PINTA 745 Clinical Trial for Protein Energy Wasting in Patients With End Stage Renal Disease
Atara Bio to Host Conference Call and Webcast Today at 8:00 a.m. Eastern Time 
From GlobeNewswire News Releases
Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes (CMV-CTL), a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Ref
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic... 
From GlobeNewswire News Releases
Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms’ Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic... 
From GlobeNewswire News Releases
Atara Biotherapeutics Announces Third Quarter 2015 Financial Results
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic... 
From GlobeNewswire News Releases
Atara Bio’s Collaborating Investigators to Present Data From Two Cellular Therapy Product Candidates at the American Society of Hematology (ASH) Annual Meeting 2015
Presentations Include Clinical and Preclinical Results in Oncology and Virus-Associated Diseases 
From GlobeNewswire News Releases
Atara Biotherapeutics Announces Participation in Three Investor Conferences
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited... 
From GlobeNewswire News Releases
Atara Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Exclusive License and Research Agreements
Atara Bio Complements Its Cytotoxic T-Cell Programs to Develop Potential Additional Treatments for Certain Cancers and Autoimmune Disorders 
From GlobeNewswire News Releases
Atara Bio Receives FDA Orphan Drug Designation for STM 434, Atara Bio's Activin Inhibitor for Ovarian Cancer
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited... 
From GlobeNewswire News Releases
Atara Bio to Host Investor Day on October 21, 2015
Atara Biotherapeutics, Inc., (Nasdaq:ATRA), today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, October 21, 2015 at 12:00p.m. ET in New York,... 
From GlobeNewswire News Releases
Atara Bio’s PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet
Preclinical Data Published in the International Journal of Obesity 
From GlobeNewswire News Releases
Atara Bio’s Collaborating Investigators to Present Data at the American Society of Nephrology Kidney Week 2015
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that its collaborating... 
From GlobeNewswire News Releases
Atara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia
Data Presented at the 15th International Myeloma Workshop 
From GlobeNewswire News Releases
Atara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in September 2015
From GlobeNewswire News Releases
Atara Biotherapeutics Announces Completion of Enrollment in PINTA 745 Phase 2 Clinical Trial in End-Stage Renal Disease Patients With Protein Energy Wasting
Preliminary Top-Line Data Expected by the End of the Fourth Quarter of 2015 
From GlobeNewswire News Releases
Atara Biotherapeutics Announces Second Quarter 2015 Results
From GlobeNewswire News Releases
Atara Bio Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From GlobeNewswire News Releases
Atara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock
From GlobeNewswire News Releases
Atara Bio Announces Proposed Offering of Common Stock
From GlobeNewswire News Releases
Critical Alerts For Juno Therapeutics Inc, Cigna, Atara Biotherapeutics, TASER International and Halliburton Released By InvestorsObserver
From PR Newswire
Atara Biotherapeutics Exercises Exclusive License to T-Cell Technology From Memorial Sloan Kettering Cancer Center
Activated T-Cell Technology Designed to Harness Immune System to Fight Cancer and Infectious Disease 
From GlobeNewswire News Releases
Atara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in June 2015
From GlobeNewswire News Releases
Update: Atara Biotherapeutics' Collaborating Investigators to Present Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV+ Lymphoma after Hematopoietic and Solid Organ Allografts at the 2015 American Society of Clinical... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.